Biochemical and Biophysical Research Communications 1988-01-29

The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vitro.

M Gschwendt, W Kittstein, F Marks

Index: Biochem. Biophys. Res. Commun. 150(2) , 545-51, (1988)

Full Text: HTML

Abstract

Various biological effects induced by the tumor promoting phorbol ester TPA in mouse skin are comparably suppressed by the immunologically inactive cyclosporine H (CsH) and by the strongly immunosuppressive cyclosporine A (CsA). These effects inhibited include the development of edema, stimulation of alkaline phosphatase activity, DNA and protein synthesis, as well as tumor promotion. Furthermore, CsH, like CsA, inhibits the Ca2+/calmodulin-dependent phosphorylation of the elongation factor 2 (EF-2) in vitro and the TPA-induced increases in the amount of EF-2 in vivo. Similar observations were made using the weak immunosuppressant CsD. We conclude from these results that the ability of cyclosporines to act as immunosuppressants and their ability to inhibit TPA-effects are based on two different mechanisms of action. Inhibition of TPA-effects may involve suppression of calmodulin-dependent processes, such as augmentation and phosphorylation of EF-2.


Related Compounds

  • Val2-Cyclosporine

Related Articles:

Antimalarial activity of cyclosporins A, C and D.

1994-03-01

[Afr. J. Med. Med. Sci. 23(1) , 47-51, (1994)]

Enzymatic synthesis of cyclosporin A.

1987-12-25

[J. Biol. Chem. 262(36) , 17258-9, (1987)]

In vitro and in vivo comparative studies on immunosuppressive properties of cyclosporines A, C, D and metabolites M1, M17 and M21.

1993-01-01

[Immunopharmacol. Immunotoxicol. 15(2-3) , 163-77, (1993)]

Does the binding of cyclosporine to calmodulin result in immunosuppression?

1986-10-03

[Science 234(4772) , 68-71, (1986)]

Synergistic effects of cyclosporin analogs--A, D, G, IMM-125--with rapamycin and/or brequinar.

2006-05-31

[Transplant. Proc. 26(5) , 3021-4, (1994)]

More Articles...